ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Cancer Treatment Centers of America, Phoenix. 403

Goodyear, Arizona, United States, 85338

Principal Investigator: Dennis Scribner, MD         

Honor Health, USOR, 406

Phoenix, Arizona, United States, 85082

Principal Investigator: Bradley Monk, MD         

Nuvance Health System, 401

Danbury, Connecticut, United States, 06856

Principal Investigator: Linus Chuang, MD         

Baptist MD Anderson Cancer Center, 404

Jacksonville, Florida, United States, 32207

Principal Investigator: Lauren Hand, MD         

Cancer Treatment Centers of America, Atlanta. 415

Newnan, Georgia, United States, 30265

Principal Investigator: Ruchi Garg, MD         

Sudarshan Sharma, MD. LTD. 414

Hinsdale, Illinois, United States, 60521

Principal Investigator: Sudarshan Sharma, MD         

Cancer Treatment Centers of America, Chicago. 410

Zion, Illinois, United States, 60099

Principal Investigator: Barber Buttin, MD         

Baptist Health Lexington, 407

Lexington, Kentucky, United States, 40503

Principal Investigator: Monica Vetter, MD         

Norton Cancer Institute – St. Matthews, 416

Louisville, Kentucky, United States, 40207

Principal Investigator: Mary Gordinier, MD         

Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409

Shreveport, Louisiana, United States, 71103

Principal Investigator: Destin Black, MD         

Minnesota Oncology Hematology, P. A. – USOR, 421

Maplewood, Minnesota, United States, 55109

Principal Investigator: Jessica thomas-Pepin, MD         

Center of Hope, 413

Reno, Nevada, United States, 89511

Principal Investigator: Peter Lim, MD         

The Valley Hosptial, Inc. 411

Ridgewood, New Jersey, United States, 07450

Principal Investigator: Amanda Podolinski, MD         

Women’s Cancer Care Associates, LLC. 405

Albany, New York, United States, 12208

Principal Investigator: Joyce Barlin, MD         

The Ohio State University James Cancer Center, 412

Columbus, Ohio, United States, 43210

Principal Investigator: David O’Malley, MD         

Oncology Associates of Oregon, P. C. – USOR. 419

Eugene, Oregon, United States, 97401

Principal Investigator: Charles Anderson, MD         

Texas Oncology, P. A. – Austin, USOR. 417

Austin, Texas, United States, 78731

Principal Investigator: Helen Eshed, MD         

Texas Oncology, P.A., Fort Worth – USOR. 420

Fort Worth, Texas, United States, 76104

Principal Investigator: Noelle Cloven, MD         

Texas Oncology, P. A. Woodlands – USOR, 418

The Woodlands, Texas, United States, 77380

Principal Investigator: Christine Lee, MD         

Medical College of Wisconsin, 408

Milwaukee, Wisconsin, United States, 53226

Principal Investigator: Elizabeth Hopp, MD         

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 29, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments